Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Teclistamab in Multiple Myeloma: NCT07638683 Clinical Landscape Report 2026
16 September 2026
NCT07638683 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
ALK.CAR-T cells(University of Turin/Boston Children) in Metastatic Clear Cell Renal Cell Carcinoma: NCT07645690 Clinical Landscape Report 2026
16 September 2026
NCT07645690 clinical landscape for Metastatic Clear Cell Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development…
9 min read
Bevacizumab in Metastatic Carcinoma to the Uterine Cervix: NCT07645625 Clinical Landscape Report 2026
16 September 2026
NCT07645625 clinical landscape for Metastatic Carcinoma to the Uterine Cervix: endpoints, sponsor, phase, geography, readouts, asset context and development…
9 min read
Azacitidine in Acute Myeloid Leukemia: NCT07645469 Clinical Landscape Report 2026
16 September 2026
NCT07645469 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Gentamicin Sulfate in Urinary Bladder, Neurogenic: NCT07643974 Clinical Landscape Report 2026
16 September 2026
NCT07643974 clinical landscape for Urinary Bladder, Neurogenic: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Clofarabine in Acute Myeloid Leukemia: NCT07644481 Clinical Landscape Report 2026
16 September 2026
NCT07644481 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Sintilimab in Sarcoma: NCT07648069 Clinical Landscape Report 2026
16 September 2026
NCT07648069 clinical landscape for Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CHT-101 in Metastatic Renal Cell Carcinoma: NCT07647744 Clinical Landscape Report 2026
16 September 2026
NCT07647744 clinical landscape for Metastatic Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
[177Lu]Lu-zolbetuximab in Glioblastoma, IDH-Wildtype: NCT07648823 Clinical Landscape Report 2026
16 September 2026
NCT07648823 clinical landscape for Glioblastoma, IDH-Wildtype: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ropeginterferon alfa-2b-NJFT in Acute Myeloid Leukemia: NCT07646821 Clinical Landscape Report 2026
16 September 2026
NCT07646821 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Gamgertamig in Multiple Myeloma: NCT07648459 Clinical Landscape Report 2026
16 September 2026
NCT07648459 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Lenalidomide in Plasma Cell Leukemia: NCT07652905 Clinical Landscape Report 2026
16 September 2026
NCT07652905 clinical landscape for Plasma Cell Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.